Investment
Features
FeesSafety
Academy
More
Pluang+

Compare American Express Co (AXP) vs Ginkgo Bioworks Holdings Inc (DNA) Price & Performance

American Express CoTrade
Ginkgo Bioworks Holdings IncTrade

Price performance (Past 24H)

Key statistics

American Express Co vs Ginkgo Bioworks Holdings Inc — how do they compare? American Express Co trades at $341.53 (market cap $230.15B), while Ginkgo Bioworks Holdings Inc trades at $7.43 (market cap $505.73M). The key difference: American Express Co is far larger — about 455.1× Ginkgo Bioworks Holdings Inc's market cap, and American Express Co pays a 1.11% dividend while Ginkgo Bioworks Holdings Inc pays none. Which is the better fit depends on your goals.

AXPDNA
Market Cap
$230.15B$505.73M
Sector
FinancialsHealth
52-Week High
$384.82$16.14
52-Week Low
$292.27$5.48
Dividend Yield
1.11%
Enterprise Value
$607.68M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

American Express Co

AXP trades at $341.25, up 0.7% on the day, with a bullish technical signal and strong support at $339. Revenue grew to $72.23B in 2025, with net income of $10.83B and a 15.07% net margin. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Buy with a $369.42 price target. News highlights Amex Ventures' AI investments and premium cardmember perks.

Outlook is positive given earnings momentum and strategic AI bets, but risks include rising debt levels and competitive pressure. The stock offers growth potential with a reasonable P/E of 20.68, though investors should watch for economic sensitivity in consumer spending.

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.

DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About American Express Co

American Express Company is a global payment and travel company. The Company's principal products and services are charge and credit payment card products and travel-related services offered to consumers and businesses around the world.

Read more on AXP

About Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.

Read more on DNA